Journal article
Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging
The Journal of nuclear medicine (1978), Vol.31(6), pp.1020-1024
06/1990
Handle:
https://hdl.handle.net/2376/106886
PMID: 2348231
Abstract
Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease. Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication. Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown. Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.). Baseline circumflex coronary blood flows did not differ significantly among treatment groups. Dipyridamole significantly increased coronary blood flow before and after 7.5 or 15 mm/kg i.v. pentoxifylline (p less than 0.002). Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01). We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.
Metrics
5 Record Views
Details
- Title
- Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging
- Creators
- K A Brown - Cardiology Unit, University of Vermont College of Medicine, BurlingtonB K Slinker
- Publication Details
- The Journal of nuclear medicine (1978), Vol.31(6), pp.1020-1024
- Academic Unit
- Integrative Physiology and Neuroscience, Department of
- Publisher
- United States
- Identifiers
- 99900546997501842
- Language
- English
- Resource Type
- Journal article